Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Protective effect and application of magnesium lithospermate B or pharmaceutical composition containing lithospermate B on hepatic ischemia reperfusion

A technology of salvia miltiorrhiza magnesium acetate, liver ischemia, applied in the directions of drug combination, medical preparation containing active ingredients, pharmaceutical formula, etc. Clear protective effect, reduce the effect of complications

Inactive Publication Date: 2020-09-22
SHANGHAI INST OF MATERIA MEDICA CHINESE ACAD OF SCI
View PDF5 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Only commonly used antioxidants (vitamin C, vitamin E, α-lipoic acid, reduced glutathione, N-acetylcysteine, etc.), melatonin, trimetazidine and other drugs, although to a certain extent Although it can play a protective role, it still can’t exactly alleviate the ischemia-reperfusion injury. Therefore, it is urgent to find a drug that is safe, effective and has a clear mechanism to treat or alleviate this liver injury.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Protective effect and application of magnesium lithospermate B or pharmaceutical composition containing lithospermate B on hepatic ischemia reperfusion
  • Protective effect and application of magnesium lithospermate B or pharmaceutical composition containing lithospermate B on hepatic ischemia reperfusion
  • Protective effect and application of magnesium lithospermate B or pharmaceutical composition containing lithospermate B on hepatic ischemia reperfusion

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0025] Example 1 The protective effect of salvianolate on hepatic ischemia-reperfusion

[0026] 1.1 Grouping, administration and experimental methods

[0027] C57BL / 6 mice (purchased from Shanghai Experimental Animal Co., Ltd.) were adaptively fed for three days, and randomly divided into sham operation group (Sham), ischemia-reperfusion injury group (IRI), ischemia-reperfusion injury + salvianolic acid Salvianolate 10mg / kg group, 30mg / kg group, 100mg / kg group, salvianolate (Z20050249) was dissolved in normal saline, ischemia-reperfusion injury + salvianolate 10mg / kg group, 30mg / kg The kg group and the 100mg / kg group were administered three times through the tail vein at 24h, 12h, and 1h before the operation, and each time they were given 10mg / kg, 30mg / kg, and 100mg / kg salvianolate, except for the sham operation group. The rest of the groups were constructed according to literature reports (Ge, M., et al., Brg1-mediated Nrf2 / HO-1 pathway activation alleviates hepatic ischemia...

Embodiment 2

[0033] Example 2 Protective effect and mechanism of magnesium acetate of salvia miltiorrhiza on liver ischemia-reperfusion

[0034] Salvianolic magnesium acetate is the main active ingredient of salvianolic acid salt. Because the above experiments have proved that salvianolate reaches the maximum efficacy dose at a dose above 30mg / kg, the following experiment selects the clinical dose of salvianolic acid magnesium 30mg / kg as the efficacy dose for mechanism research.

[0035] 2.1. C57BL / 6 mice were fed adaptively for three days, and randomly divided into sham operation (Sham) group, ischemia-reperfusion injury (IRI) group, ischemia-reperfusion injury+magnesium salvia acetate (IRI+MLB) 30mg / kg In the group, magnesium acetate of salvia miltiorrhiza (Xuanlijiang Group, Shanghai Institute of Materia Medica, Chinese Academy of Sciences) was dissolved in normal saline, and administered three times via the tail vein at 24h, 12h, and 1h before the operation, 30mg / kg each time. Except ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention provides an application of magnesium lithospermate B or a pharmaceutical composition containing the lithospermate B in preparation of a medicine. The medicine is used for treating and / orpreventing liver injury, especially liver injury caused by hepatic ischemia reperfusion. According to the invention, a mouse hepatic ischemia reperfusion animal model is utilized to systematically prove the treatment and protection effects of the magnesium lithospermate B or the pharmaceutical composition containing the magnesium lithospermate B, such as salvianolate, on hepatic ischemia reperfusion for the first time, the internal mechanism of the medicine is clarified, and a theoretical basis is provided for clinical application.

Description

technical field [0001] The invention belongs to the field of medical applications, and in particular relates to the application of magnesium salvia acetate or a pharmaceutical composition containing magnesium salvia acetate in the preparation of medicines for treating and / or preventing liver damage, especially those caused by liver ischemia-reperfusion Medicines for liver damage. Background technique [0002] The liver is the largest substantial organ of the human body and one of the important metabolic organs of the human body. Its functions mainly include the generation and secretion of bile, lipid and sugar metabolism, detoxification, blood coagulation, and regulation of blood circulation. The liver is also an important immune organ. It protects the health of the body by phagocytizing, isolating, and eliminating various invading and endogenous pathogens. While the liver plays a role in detoxification and immunity, it will also be invaded by endogenous and exogenous toxic...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K31/343A61P1/16A61P9/10
CPCA61K31/343A61P1/16A61P9/10
Inventor 宣利江潘国宇
Owner SHANGHAI INST OF MATERIA MEDICA CHINESE ACAD OF SCI
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com